RedHill Biopharma (RDHL) Equity Ratio: 2014-2024
Historic Equity Ratio for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2024 value amounting to 0.26.
- RedHill Biopharma's Equity Ratio fell 22.22% to 22.75 in Q2 2025 from the same period last year, while for Jun 2025 it was 22.75, marking a year-over-year decrease of 22.22%. This contributed to the annual value of 0.26 for FY2024, which is 389.11% down from last year.
- RedHill Biopharma's Equity Ratio amounted to 0.26 in FY2024, which was down 389.11% from 0.09 recorded in FY2023.
- RedHill Biopharma's Equity Ratio's 5-year high stood at 0.09 during FY2023, with a 5-year trough of 0.30 in FY2022.
- In the last 3 years, RedHill Biopharma's Equity Ratio had a median value of 0.26 in 2024 and averaged 0.16.
- In the last 5 years, RedHill Biopharma's Equity Ratio plummeted by 721.96% in 2022 and then soared by 129.47% in 2023.
- Over the past 5 years, RedHill Biopharma's Equity Ratio (MRY) stood at 0.08 in 2020, then plummeted by 36.32% to 0.05 in 2021, then tumbled by 721.96% to 0.30 in 2022, then surged by 129.47% to 0.09 in 2023, then plummeted by 389.11% to 0.26 in 2024.
- Its Equity Ratio stands at 0.26 for FY2024, versus 0.09 for FY2023 and 0.30 for FY2022.